Dr. Dongliang Chen 陈冬良
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, immunotherapy, and multidisciplinary care for digestive system tumors, including colorectal, gastric, esophageal, liver, and pancreatic cancers.
Dr. Chen is a Chief Physician and doctoral supervisor. The doctor leads or participates in research projects funded by the National Key R&D Program, National Natural Science Foundation, Guangdong Provincial Natural Science Foundation, and Sun Yat-sen University. Dr. Chen has published over 30 SCI papers in international journals such as Hepatology and JNCI.
Professional roles
- Member, Youth Professional Committee of Gastroenterology, China Anti-Cancer Association
- Standing Committee Member, Tumor Metabolism Professional Committee, Guangdong Anti-Cancer Association
- Standing Committee Member, Youth Digestive Tumor Differentiation Committee, Guangzhou Anti-Cancer Association
- Review Expert, Guangdong Provincial Natural Science Foundation
Name order: in Chinese the family name comes first (Chen Dongliang). Papers usually list the name as Dongliang Chen or Chen D.
Selected publications
46 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Theranostics, 2025 (first author): Erratum: Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression: Erratum. PubMed 39897561
- Mol Cancer, 2024 (senior author): Circular RNA circPHLPP2 promotes tumor growth and anti-PD-1 resistance through binding ILF3 to regulate IL36γ transcription in colorectal cancer. PubMed 39695693
- Cancer Drug Resist, 2024 (first author): Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer. PubMed 38510750
- J Gastroenterol Hepatol, 2023 (senior author): Circular RNA circTNIK promotes tumor progression and metastasis in gastric cancer by regulating ZEB2. PubMed 37078141
- Front Oncol, 2023 (senior author): Case report: PD-1 inhibitor-based treatment strategies in gastric cancer complicated by bone marrow metastasis and disseminated intravascular coagulation: A report of two cases. PubMed 36910633
- J Pers Med, 2023 (senior author): Comprehensive Analysis of Clinicopathological and Molecular Features to Predict Anti-PD-1-Based Therapy Efficacy in Patients with Advanced Gastric Signet Ring Cell Carcinoma. PubMed 36675776
- Mol Cancer, 2021 (first author): The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. PubMed 34911533
- J Exp Clin Cancer Res, 2021 (first author): Correction to: Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. PubMed 34167550
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion